<div id="readability-page-1"><p>Annexon, Inc. (NASDAQ:ANNX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Annexon in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $0.56 for the year, up from their prior estimate of $0.43. The consensus estimate for Annexon's current full-year earnings is ($1.13) per share.</p><p>Several other research analysts have also recently weighed in on the stock. Chardan Capital  reaffirmed a &#34;buy&#34; rating and issued a $16.00 price target on shares of Annexon in a report on Friday, March 20th. Cantor Fitzgerald  restated an &#34;overweight&#34; rating on shares of Annexon in a research report on Wednesday, January 14th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Annexon in a research note on Monday, April 20th. Finally, Wall Street Zen raised Annexon from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p><p><b>Check Out Our Latest Research Report on Annexon</b></p><h2>Annexon Price Performance</h2><p>NASDAQ ANNX opened at $5.69 on Monday. The company's 50 day simple moving average is $5.69 and its two-hundred day simple moving average is $5.08. Annexon has a 1 year low of $1.60 and a 1 year high of $7.18. The stock has a market capitalization of $932.25 million, a PE ratio of -4.66 and a beta of 1.22. </p><p>Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. </p><h2>Insider Transactions at Annexon</h2><p>In related news, EVP Michael Overdorf sold 6,225 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $31,747.50. Following the transaction, the executive vice president owned 124,464 shares of the company's stock, valued at $634,766.40. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CFO Jennifer Lew sold 7,851 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,118.61. Following the sale, the chief financial officer owned 113,765 shares in the company, valued at $581,339.15. The trade was a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 32,513 shares of company stock worth $165,973. Company insiders own  12.67% of the company's stock. </p><h2>Hedge Funds Weigh In On Annexon</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of ANNX. AQR Capital Management LLC increased its position in shares of  Annexon by 122.6% during the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company's stock valued at $142,000 after purchasing an additional 40,637 shares during the last quarter.  Jane Street Group LLC lifted its position in  Annexon by 8.2% in the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock worth $193,000 after buying an additional 7,553 shares during the last quarter.  Acadian Asset Management LLC lifted its position in  Annexon by 31.1% in the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company's stock worth $393,000 after buying an additional 48,345 shares during the last quarter.  Geode Capital Management LLC boosted its stake in  Annexon by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company's stock worth $5,484,000 after buying an additional 39,763 shares in the last quarter.  Finally, American Century Companies Inc. grew its position in  Annexon by 6.6% during the second quarter. American Century Companies Inc. now owns 211,195 shares of the company's stock valued at $507,000 after acquiring an additional 13,001 shares during the last quarter. </p><h2>Annexon Company Profile</h2> (Get Free Report)<p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.  </p><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Annexon</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Annexon Right Now?</h2><p>Before you consider Annexon, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p><p>While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANNX

<p>HC Wainwright has raised its FY2030 EPS estimate for Annexon, Inc. to $0.56 from $0.43, while the consensus estimate for the current year is ($1.13) per share. The stock has received mixed ratings from analysts, with five Buy ratings, one Hold, and one Sell. Annexon shares opened at $5.69, with a market cap of $932.25 million. Recent insider sales and institutional investments have also been noted, indicating active trading around the stock. The company focuses on developing therapies for neurodegenerative diseases.</p>

HC Wainwright Has Optimistic View of Annexon FY2030 Earnings